IMCR - Immunocore Kimmtrak for eye cancer backed by EMA panel for EU approval

Immunocore (NASDAQ:IMCR) said a committee of the European Medicines Agency (EMA) recommended the approval of its drug Kimmtrak (tebentafusp) to treat  HLA-A 02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), a type of cancer affecting the eye. The recommendation by the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 IMCgp100-202 clinical trial. The company said that Kimmtrak, if approved, will be the first and only treatment option approved in Europe to treat patients with unresectable or metastatic uveal melanoma. Kimmtrak was approved in the U.S. in January.

For further details see:

Immunocore Kimmtrak for eye cancer backed by EMA panel for EU approval